Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Trial Profile

PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TREnd
  • Most Recent Events

    • 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 31 Aug 2018 Biomarkers information updated
    • 11 Jun 2018 Results examining the activity of palbociclib published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top